Spectrum Pharmaceuticals acquires remaining 50% stake in RIT Oncology from Cell Therapeutics - MarketLine Financial Deals

Spectrum Pharmaceuticals acquires remaining 50% stake in RIT Oncology from Cell Therapeutics

Spectrum Pharmaceuticals acquires remaining 50% stake in RIT Oncology from Cell Therapeutics - MarketLine Financial Deals
Spectrum Pharmaceuticals acquires remaining 50% stake in RIT Oncology from Cell Therapeutics
Published Mar 16, 2009
2 pages — Published Mar 16, 2009
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, has acquired the remaining 50% ownership interest in the Zevalin joint venture, RIT Oncology, LLC, from Cell Therapeutics, Inc. (CTI), a biopharmaceutical company focused on the development of oncology drugs.

  
Source:
Document ID
MA01854_090225
Country
Ticker
CTIC=US
Ticker
SPPI=US
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Spectrum Pharmaceuticals acquires remaining 50% stake in RIT Oncology from Cell Therapeutics" Mar 16, 2009. Alacra Store. Dec 03, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Spectrum-Pharmaceuticals-acquires-remaining-50-stake-in-RIT-Oncology-from-Cell-Therapeutics-2052-1774>
  
APA:
MarketLine Financial Deals. (2009). Spectrum Pharmaceuticals acquires remaining 50% stake in RIT Oncology from Cell Therapeutics Mar 16, 2009. New York, NY: Alacra Store. Retrieved Dec 03, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Spectrum-Pharmaceuticals-acquires-remaining-50-stake-in-RIT-Oncology-from-Cell-Therapeutics-2052-1774>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.